Research and Practice in Thrombosis and Haemostasis

Titel Veröffentlichungsdatum Sprache Zitate
HTRS2023.P4.13 Antibody mediated pathophysiology of immune thrombotic thrombocytopenic purpura2023/08/01English
HTRS2023.P4.14 Using heparin-calibrated assays to estimate anti-factor Xa activity of factor Xa inhibitors: correlation analysis of published data2023/08/01English
HTRS2023.P2.1 Will my patient bleed? Management and outcomes for patients with severe FXI deficiency2023/08/01English
HTRS2023.P2.20 Common documentation errors in the electronic health records of persons with hemophilia B2023/08/01English
HTRS2023.O8B.4 Fatty acid oxidation fuels agonist-induced platelet activation and thrombus formation: targeting beta-oxidation of fatty acids as an effective anti-platelet strategy2023/08/01English
HTRS2023.P3.5 Screening for abnormal uterine bleeding in adolescents presenting to primary care clinics2023/08/01English
HTRS2023.P4.21 Multi-ancestry GWAS for venous thromboembolism identifies novel loci after validation in zebrafish2023/08/01English
HTRS2023.O8A.3 Bringing PERT to pediatrics: implementing and examining outcomes of the first pediatric Pulmonary Embolism Response Team (PERT)2023/08/01English
HTRS2023.O6A.4 Proteomic analysis reveals proteins that are differently expressed in factor XI-deficient non-bleeders and bleeders2023/08/01English
Editorial Board2023/08/01English
Title page2023/08/01English
HTRS2023.P2.13 Off-target toxicity of CART cell therapy in murine hemophilia A with inhibitors2023/08/01English
HTRS2023.P1.6 Characterization and expression of atypical type 2B variants in the Zimmerman Program2023/08/01English
HTRS2023.P4.10 Endothelial ERp46 supports tissue factor activity2023/08/01English
HTRS2023.P1.3 HMGB1 contributes to platelet activation in sickle cell disease through enhancement of purinergic signaling2023/08/01English
HTRS2023.O6A.2 Mobile application measurement of menstrual cycle characteristics and its association with dysmenorrhea and activity limitation in early adolescents2023/08/01English
HTRS2023.O6B.3 FVIII deficiency leads to lower atherogenic ApoB-lipoprotein and higher fibrinolysis2023/08/01English
Tissue factor-heparanase complex: intracellular nonhemostatic effects2023/08/01English
Citrullination of α2-antiplasmin is unlikely to contribute to enhanced plasmin generation in COVID-19 pathophysiology2023/08/01English
HTRS2023.P4.11 Platelet-associated beta-2 glycoprotein 1 inhibits agonist-induced platelet activation which is relieved by proteolytic cleavage2023/08/01English
HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders2023/08/01English
HTRS2023.P2.2 Mim8 clinical development program: an overview of FRONTIER studies with results from a multiple ascending dose study of Mim8 in patients with severe hemophilia A with or without factor VIII inhibitors2023/08/01English
HTRS2023.P2.22 Evaluating the effectiveness and safety of damoctocog alfa pegol prophylaxis in hemophilia A patients with a history of factor VIII inhibitors from the real-world HEM-POWR study2023/08/01English
HTRS2023.O8A.1 Plasmic (PLASMICkid) score for pediatric thrombotic thrombocytopenic purpura2023/08/01English
HTRS2023.P4.8 Pediatric patients diagnosed with a pulmonary embolism are more likely to be diagnosed with dyspnea three or more months after diagnosis: a population-based analysis2023/08/01English
HTRS2023.P3.7 Descriptive analysis of a pediatric anticoagulation stewardship initiative to improve anticoagulation safety: a quality improvement project2023/08/01English
Aims and Scope2023/08/01English
HTRS2023.O8A.4 Proton pump inhibitors are an additive risk factor for hormonal contraception related thrombosis2023/08/01English
HTRS2023.P2.12 Reactivation of factor 8 inhibitor on emicizumab prophylaxis in a previously tolerized patient2023/08/01English
HTRS2023.P4.12 Perceptions on the potential for artificial intelligence to improve venous thromboembolism prevention2023/08/01English